Bangalore: The Janata Dal (Secular), or JD(S), led by former prime minister H.D. Deve Gowda, has selected Anita Kumaraswamy, the party chief’s daughter-in-law, as a candidate for the by-elections to be held in Karnataka on 27 December. She is the wife of former Karntaka chief minister Kumaraswamy.
The by-elections in eight constituencies are crucial for Karnataka’s ruling Bharatiya Janata Party(BJP) government to increase its majority in the state assembly.
Anita Kumaraswamy, the fourth member of Deve Gowda’s family to enter politics, will contest the election from Madhugiri where she faces C. Chennigappa, a former JD(S) loyalist who is now the BJP’s candidate.
— Staff Writer
Pharma volunteer dies before second dose
Hyderabad: A 24-year old volunteer enrolled in a bioequivalence study being conducted by Hyderabad based contract research firm, GVK Biosciences Pvt. Ltd died on Friday night, a day before he was to take the second dose. Local editions of ‘The Times of India’ and ‘The Hindu’ reported this on Sunday.
The bioequivalence study was for Felodipine, an anti-hypertension drug—the patent for this, held by AstraZeneca Plc., expired in 2007. Bioequivalence study for efficacy is required before a company can introduce a generic version of a drug that is already being marketed.
According to the company spokesperson Sharada Alvakonda, “as per approved protocol, Surender was administered the 1st dose on 26 November and discharged in healthy condition on 29 November.” The spokesperson also said that the particular drug washes out from the body within four days at the most. For receiving the second dosage on 6 December, Surender was scheduled to be admitted on 5 December.
When Surender reported to GVK Biosciences on 5 December, the ninth day after his first dose, he complained of discomfort in his chest and died while being taken to a nearby hospital by in-house doctors at GVK.
In a release, GVK Bio said that the company is “not aware of the cause of his death which will be determined by the post-mortem report.” According to the company, the post-mortem report is expected in a week. “We also understand that Surender has been taking part in similar bioequivalence studies in various CROs and has taken part in similar studies in GVK Bio in the past,” Sharada said. As many as 65 other volunteers, who were part of the study, were given the second dosage on 6 December.
— Lison Joseph